8 / 18
Page 62
conferenceseries
.com
Volume 2, Issue 4 (Suppl)
Breast Can Curr Res, an open access journal
Breast Pathology 2017
August 23-24, 2017
August 23-24, 2017 Toronto, Canada
4
th
World Congress on
Breast Pathology and Cancer Diagnosis
Breast Can Curr Res 2017, 2:4 (Suppl)
DOI: 10.4172/2572-4118-C1-009
Locoregional surgery in metastatic breast cancer
Badria Eid
King Faisal Specialist Hospital and Research Centre, Saudi Arabia
Background:
A current guidelines do not recommend locoregional surgery for metastatic breast cancer at presentation
despite some studies suggesting a survival benefits. We aimed to assess outcomes in patients with metastatic breast cancer who
underwent surgery.
Methods:
In a cohort study of all metastatic breast cancer diagnosed at single institution between 2000 and 2012, we assessed
patient survival in the context of demographics, clinical and histopathology characteristics, metastatic burden, and type of
surgery performed.
Results:
678 patients with metastatic breast cancer were included, 412 (60.77%) underwent surgery for primary tumor, with
a median follow-up of 41 months. Patients in the surgery group had longer survival (3.1 vs. 1.9 years, P<0.0001). The surgery
group had longer survival (41 versus 27months, p<0.0029). The 5 year survival rate for surgery group was 34% compared with
14% for the nonsurgery group. A multivariate analysis revealed surgery (p=0.0003), large tumor size (p=0.0195), ER positive
(p<0.0001), and metastasis at presentation (p=0.0032) were prognostic variables.
Conclusions:
Locoregional surgery does confer a survival advantage in stage iv breast cancer.
badria_eid@yahoo.com